Journal
LEUKEMIA RESEARCH
Volume 37, Issue 12, Pages 1636-1641Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2013.09.023
Keywords
Nucleostemin; Acute myeloid leukemia; Risk stratification; Minimal residual disease
Categories
Funding
- Chinese Ministry of Education [2011JC043]
- Hubei Province Natural Science Fund [2012FFB02609]
- Wuhan Science and Technology Bureau [201150431122]
Ask authors/readers for more resources
To clarify the role of nucleostemin (NS) in AML, its transcription levels in bone marrow (BM) samples obtained from 128 newly diagnosed AML patients were analyzed. We determined that the highest NS transcription level was in M1 patients, while the lowest NS transcription level was in M3 patients. NS mRNA expression is positively correlated with blast percentages (%) and CD34, CD117 and CD123 antigen expression in BM samples but is unrelated to the transcription level of WTI. A significant difference in NS expression between poor-risk and better-risk and between poor-risk and intermediate-risk AML patients was found. Our initial data indicated that NS can be used for tracking minimal residual disease (MRD) and is a helpful guide for treatment. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available